The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
November 19th 2024
Abelacimab is an investigational, selective, fully human monoclonal antibody.
Advancing Chronic Worsening Heart Failure Treatment: The Critical Role of Pharmacists in Therapy Integration
1.0 Credit / Cardiology
View More
Iron Deficiency and Anemia in Heart Failure: Clinical Applications for the Use of Intravenous Iron
1.5 Credits / Cardiology
View More
Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejec...
1.0 Credits / Cardiology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
Recent Developments in the Management of Heart Failure With Preserved Ejection Fraction
1.0 Credit / Cardiology
View More
Therapies in Lowering LDL-Cholesterol Levels for the Primary and Secondary Prevention of Atherosclerotic Cardi...
0.75 Credit / Cardiology
View More
Updated Guidelines in the Management of Atrial Fibrillation and Application for Pharmacists
1.5 Credits / Cardiology
View More
The Expanding Role of Nonstatin Therapies in Reducing LDL-Cholesterol Levels to Prevent and Manage ASCVD: A Re...
1.5 Credits / Cardiology
View More
Elevating Cardiac Care: Insights From Pharmacists Across Practice Settings
1.0 Credit / Cardiology
View More
The Evolving Treatment Paradigm for the Management of Pulmonary Arterial Hypertension: Strategies to Optimize ...
1.5 Credits / Cardiology
View More
Optimizing Care for Chronic Worsening Heart Failure: The Key Role of Pharmacists in Integrating Therapies
1.5 Credits / Cardiology
View More
Lipoprotein(a) and Beyond: Emerging Paradigms in Atherosclerotic Cardiovascular Disease Prevention
1.5 Credits / Cardiology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Trends in the ASCVD, LDL-C Management Treatment Landscape in 2022
January 27th 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
Watch
Study Finds Heart Function Recovered Quickly in Children with COVID-19-Related MIS-C Condition
January 26th 2022Some study limitations include that follow-up data were missing for some patients who dropped out of the study during the follow-up stages and the timing of the follow-up echocardiograms were random and driven by preference versus standard protocol.
Read More
AHA Advises Oral, Not Injectable, Penicillin to Treat High-Risk Rheumatic Heart Disease
January 21st 2022In a presidential advisory, the American Heart Association says that individuals thought to be having an allergic response to the injection may instead by experiencing a cardiac reaction.
Read More
The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD
January 21st 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Watch
How Inclisiran Helps to Manage LDL-C for Patients With ASCVD
January 20th 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran, discussed the trial results assessing the efficacy and safety of inclisiran for patients with atherosclerotic cardiovascular disease.
Watch